Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on August 13, 2018. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new Chief Financial Officer (CFO) and Secretary. The company is incorporated in Nevada and operates in the life sciences and medical device sector.

Key Financial Metrics

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.

Material Changes

  • Departure of CFO: Maximilian Scheder-Bieschin retired as Chief Financial Officer and Secretary effective August 13, 2018. He will remain an employee through the end of August and serve as a consultant until December 31, 2018, under a Transition Services Agreement.
  • Appointment of New CFO: John (Jack) Glenn was appointed as the new Chief Financial Officer and Secretary, effective August 13, 2018.

Compensation, Outlook, and Risks

New CFO Compensation Package

  • Base Salary: $275,000 annually, subject to Board increase.
  • Signing Bonus: $25,000.
  • Annual Bonus: Target of 40% of base salary, contingent on operational and financial milestones.
  • Equity Grant: Option to purchase 400,000 shares of common stock at fair market value. Vesting schedule: 25% on the first anniversary, with the remainder vesting monthly (1/48th per month) thereafter.
  • Future Equity: Eligible for an additional option grant in 2019 with a fair value no less than an option for 100,000 shares.

Severance and Change of Control

  • Termination Without Cause (Pre-Anniversary): 6 months of base salary plus COBRA premiums.
  • Termination Without Cause (Post-Anniversary): 9 months of base salary plus COBRA premiums.
  • Change of Control: If terminated without cause within one year of a change of control, the executive receives 9 months of base salary, a prorated target bonus, continued health coverage, and acceleration of all unvested equity.

Management Commentary

Mr. Glenn brings 25 years of financial leadership experience in the life sciences industry, including prior CFO roles at Sonendo Inc., Armetheon, Inc., and Solta Medical, Inc. The Board determined his compensation to be competitive and aligned with the company's strategic needs.

Investor Verification Checklist

  • Verify the exact vesting schedule and fair market value determination date for the 400,000 share option grant.
  • Review the Transition Services Agreement (Exhibit 10.3) to understand the specific scope of the outgoing CFO's consulting role.
  • Confirm the impact of the new CFO's compensation on the company's future operating expenses and cash burn rate.
  • Check for any subsequent filings regarding the performance milestones tied to the annual bonus.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.